Straits Times Index
3,217.41 +10.42 (+0.32%) Nikkei
31,857.62 -14.90 (-0.05%) Hang Seng
17,809.66 +436.63 (+2.51%) FTSE 100
7,608.08 +6.23 (+0.08%) Bitcoin USD
27,022.63 +96.94 (+0.36%) CMC Crypto 200
579.66 +0.90 (+0.15%)
Spruce Biosciences, Inc. (SPRB)
After hours:
| Previous close | 2.2300 |
| Open | 2.2500 |
| Bid | 2.1600 x 800 |
| Ask | 2.3900 x 800 |
| Day's range | 2.2300 - 2.2999 |
| 52-week range | 0.9550 - 3.5700 |
| Volume | |
| Avg. volume | 70,296 |
| Market cap | 92.006M |
| Beta (5Y monthly) | 2.13 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.6300 |
| Earnings date | 08 Nov 2023 - 13 Nov 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 8.50 |
Business WireSpruce Biosciences to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
SOUTH SAN FRANCISCO, Calif., August 28, 2023--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer, will present at the H.C. Wainwright 25th Annual Global Investment Conference on September 12, 2023, at 3:30 p.m. ET.
Business WireSpruce Biosciences Reports Second Quarter 2023 Financial Results and Provides Corporate Updates
SOUTH SAN FRANCISCO, Calif., August 14, 2023--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today reported financial results for the second quarter ended June 30, 2023 and provided corporate updates.
ZacksSpruce Biosciences, Inc. (SPRB) Upgraded to Buy: Here's Why
Spruce Biosciences, Inc. (SPRB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
